• home
  • about us
    • the advantage
    • key facts
    • where we are
    • where we invest
    • management team
    • funds
  • portfolio
    • companies
    • CEOs
  • news
  • investments
    • focus
      • prevention & nutraceuticals
      • medical foods OTC, Rx
      • enabling technologies
      • brands & channels
      • diagnostics
    • criteria
    • process
  • your business
  • careers
  • contact us
    • the bahamas
    • united kingdom
    • switzerland
    • new zealand

portfolio

companies

Phagenesis

Phagenesis is a neurostimulation device company that has developed the first clinically proven treatment for dysphagia (inability to swallow safely) following a stroke. Dysphagia occurs in about half stroke patients, and leads to poor nutrition that may require tube-feeding with associated higher risk of pneumonia and early death.

Phagenesis Closes €7 Million Series B Financing Round
2011-10-04
  • Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that it has closed a €7 million Series B funding round designed to accelerate the company's development plans.

Read the full article...

Daniel Green, Phagenesis:
 "Inventages brings talent, imagination and rigor to the process of identifying suitable investments."
www.phagenesis.com
www.phagenesis.com
Back to portfolio ...
Graham Clarke, ImmunoBiology
Graham Clarke, ImmunoBiology:
"Investment capital is of course central to create a valuable business but to be successful you need more than just funds from your investors." More...
Terms Print Top
© 2012 Inventages